VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline. The company announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone reflects continued progress across the company's therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary antibody engineering, linker, and conjugation technologies.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary technologies and represents one of its more advanced development programs. The company recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies.
VERAXA now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate is critical for safeguarding the company's innovations and maintaining a competitive edge in the rapidly evolving field of antibody-based therapeutics.
VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. The advancement of VXA-222 and the expansion of its patent portfolio underscore the company's commitment to developing next-generation cancer therapies that address significant unmet medical needs.
The importance of this announcement lies in VERAXA's strategic progress in both its pipeline and intellectual property. The move of VXA-222 into the next development stage brings the company closer to potentially delivering a novel treatment option for cancer patients. Simultaneously, the strengthening of its patent portfolio protects its innovations and positions the company for future growth and potential partnerships.
Investors and industry observers are likely to view this as a positive indicator of VERAXA's execution capabilities and long-term viability. The company's focus on both advancing its lead candidates and securing broad intellectual property coverage demonstrates a comprehensive approach to building sustainable value in the competitive biotech sector.
For more information on VERAXA and its latest updates, visit the company's newsroom at https://nnw.fm/VRXA.
